Perseus ProteomicsPerseus Proteomics Inc.4882東証グロース医薬品FY ending Mar 2026, non-consolidated, J-GAAP
It lost about ¥550 for every ¥100 of sales at the operating level. Revenue changed +12.6% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -18.1% | —× | — |
| 2023 | — | —× | -26.8% | —× | — |
| 2024 | — | —× | -51.8% | —× | — |
| 2025 | — | —× | -51.5% | —× | — |
| 2026 | — | —× | -41.7% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 72 | 94 | 100 | 120 | 136 |
| Cost of revenue | 4 | 8 | 13 | 16 | 19 |
| Gross profit | 68 | 87 | 88 | 104 | 116 |
| SG&A | 540 | 784 | 982 | 930 | 861 |
| Operating income | -472 | -698 | -895 | -826 | -745 |
| Pretax income | -597 | -785 | -1,103 | -902 | -716 |
| Income tax | 2 | 2 | 2 | 2 | 2 |
| Net income attributable to owners | -599 | -787 | -1,104 | -905 | -718 |
| Operating margin | -656.4% | -740.7% | -891.1% | -686.5% | -549.8% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.21B | ¥2.44B | ¥1.54B | ¥1.67B | ¥1.52B |
| Total assets | ¥3.3B | ¥2.57B | ¥1.69B | ¥1.82B | ¥1.62B |
| Net assets | ¥3.15B | ¥2.4B | ¥1.4B | ¥1.43B | ¥1.22B |
| Share capital | ¥1.94B | ¥1.94B | ¥1.97B | ¥2.44B | ¥751.2M |
| Property, plant and equipment | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
| Intangible assets excluding goodwill | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
| Current assets | ¥3.29B | ¥2.51B | ¥1.65B | ¥1.78B | ¥1.61B |
| Current liabilities | ¥148.4M | ¥111.1M | ¥129M | ¥124.9M | ¥65.4M |
| Total liabilities | ¥148.4M | ¥170.1M | ¥295.5M | ¥386.4M | ¥405.8M |
| Equity attributable to owners of parent | ¥3.15B | ¥2.37B | ¥1.32B | ¥1.35B | ¥1.14B |
| Retained earnings | -¥1.01B | -¥1.8B | -¥2.9B | -¥3.81B | -¥718.1M |
| Treasury stock | — | -¥20K | -¥21K | -¥21K | -¥30K |
EDINET (FSA Japan)
訂正有価証券報告書－第26期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第25期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第24期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第23期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第22期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第21期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.